102 related articles for article (PubMed ID: 17661842)
1. Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets.
Normén L; Yip B; Montaner J; Harris M; Frohlich J; Bondy G; Hogg RS
HIV Med; 2007 Sep; 8(6):346-56. PubMed ID: 17661842
[TBL] [Abstract][Full Text] [Related]
2. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001.
Bonnet F; Balestre E; Thiébaut R; Mercié P; Dupon M; Morlat P; Dabis F;
HIV Med; 2004 May; 5(3):133-9. PubMed ID: 15139977
[TBL] [Abstract][Full Text] [Related]
3. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
4. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
5. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D
HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849
[TBL] [Abstract][Full Text] [Related]
6. The metabolic syndrome, an epidemic among HIV-infected patients on HAART.
Jevtović DJ; Dragović G; Salemović D; Ranin J; Djurković-Djaković O
Biomed Pharmacother; 2009 Jun; 63(5):337-42. PubMed ID: 18996676
[TBL] [Abstract][Full Text] [Related]
7. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk.
Barbaro G
Am J Ther; 2006; 13(3):248-60. PubMed ID: 16772767
[TBL] [Abstract][Full Text] [Related]
8. Clinical evidence of interaction between itraconazole and nonnucleoside reverse transcriptase inhibitors in HIV-infected patients with disseminated histoplasmosis.
Andrade RA; Evans RT; Hamill RJ; Zerai T; Giordano TP
Ann Pharmacother; 2009 May; 43(5):908-13. PubMed ID: 19401476
[TBL] [Abstract][Full Text] [Related]
9. The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment.
Crook M
Ann Clin Biochem; 2007 May; 44(Pt 3):219-31. PubMed ID: 17456292
[TBL] [Abstract][Full Text] [Related]
10. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
Manfredi R; Calza L; Chiodo F
J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Colafigli M; Di Giambenedetto S; Bracciale L; Tamburrini E; Cauda R; De Luca A
HIV Med; 2008 Mar; 9(3):172-9. PubMed ID: 18217998
[TBL] [Abstract][Full Text] [Related]
12. Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.
Palma P; Romiti ML; Cancrini C; Pensieroso S; Montesano C; Santucci MB; Bernardi S; Martino AM; Rossi P; Castelli-Gattinara G
AIDS; 2007 Nov; 21(18):2465-72. PubMed ID: 18025883
[TBL] [Abstract][Full Text] [Related]
13. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis.
Cleland LG; Caughey GE; James MJ; Proudman SM
J Rheumatol; 2006 Oct; 33(10):1973-9. PubMed ID: 16881100
[TBL] [Abstract][Full Text] [Related]
14. First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).
Carosi G; Quiros-Roldan E; Torti C; Antinori A; Bevilacqua M; Bonadonna RC; Bonfanti P; Castagna A; Cauda R; d'Arminio-Monforte A; Di Gregorio P; Di Perri G; Esposito R; Fatuzzo F; Gervasoni C; Giannattasio C; Guaraldi G; Lazzarin A; Lo Caputo S; Maggi P; Mazzotta F; Moroni M; Prestileo T; Ranieri R; Rizzardini G; Russo R; Galli M;
Infection; 2007 Jun; 35(3):134-42. PubMed ID: 17565453
[TBL] [Abstract][Full Text] [Related]
15. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.
Iloeje UH; Yuan Y; L'italien G; Mauskopf J; Holmberg SD; Moorman AC; Wood KC; Moore RD
HIV Med; 2005 Jan; 6(1):37-44. PubMed ID: 15670251
[TBL] [Abstract][Full Text] [Related]
16. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
[TBL] [Abstract][Full Text] [Related]
17. Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control.
Blass SC; Ellinger S; Vogel M; Ingiliz P; Spengler U; Stehle P; von Ruecker A; Rockstroh JK
Eur J Med Res; 2008 May; 13(5):209-14. PubMed ID: 18559303
[TBL] [Abstract][Full Text] [Related]
18. Protease inhibitors and cardiovascular disease: analysis of the Los Angeles County adult spectrum of disease cohort.
Vaughn G; Detels R
AIDS Care; 2007 Apr; 19(4):492-9. PubMed ID: 17453589
[TBL] [Abstract][Full Text] [Related]
19. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
20. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
